|14.52||-0.2550||-1.73%||Vol 415.93K||1Y Perf -16.74%|
|Dec 6th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||33.88||Analyst Rating||Moderate Buy 2.22|
|Potential %||133.41||Finscreener Ranking||★★★ 49.96|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★★★ 51.11|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★★ 50.02|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||32.42||Earnings Rating||Sell|
|Market Cap||710.71M||Earnings Date||8th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.31|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||578.81K|
|Avg. Monthly Volume||631.74K|
|Avg. Quarterly Volume||632.44K|
CryoPort Inc. (NASDAQ: CYRX) stock closed at 14.77 per share at the end of the most recent trading day (a -5.56% change compared to the prior day closing price) with a volume of 638.21K shares and market capitalization of 710.70M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Transportation industry, Industrials sector and employs 600 people. CryoPort Inc. CEO is Jerrell W. Shelton.
The one-year performance of CryoPort Inc. stock is -16.74%, while year-to-date (YTD) performance is -14.87%. CYRX stock has a five-year performance of 31.29%. Its 52-week range is between 9 and 26.01, which gives CYRX stock a 52-week price range ratio of 32.42%
CryoPort Inc. currently has a PE ratio of -2.90, a price-to-book (PB) ratio of 1.67, a price-to-sale (PS) ratio of 5.35, a price to cashflow ratio of 173.70, a PEG ratio of -, a ROA of -34.18%, a ROC of -33.20% and a ROE of -54.77%. The company’s profit margin is -15.77%, its EBITDA margin is -111.60%, and its revenue ttm is $176.92 Million , which makes it $3.61 revenue per share.
Of the last four earnings reports from CryoPort Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.31 for the next earnings report. CryoPort Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for CryoPort Inc. is Moderate Buy (2.22), with a target price of $33.88, which is +133.41% compared to the current price. The earnings rating for CryoPort Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CryoPort Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CryoPort Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.62, ATR14 : 0.89, CCI20 : 95.85, Chaikin Money Flow : 0.04, MACD : 0.91, Money Flow Index : 48.83, ROC : 10.47, RSI : 62.63, STOCH (14,3) : 64.71, STOCH RSI : 0.19, UO : 52.24, Williams %R : -35.29), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CryoPort Inc. in the last 12-months were: Baddour Linda (Sold 0 shares of value $0 ), Jerrell W. Shelton (Option Excercise at a value of $1 028 842), Jerrell W. Shelton (Sold 178 229 shares of value $3 643 792 ), Linda Baddour (Option Excercise at a value of $0), Mark W. Sawicki (Option Excercise at a value of $0), Mark W. Sawicki (Sold 2 838 shares of value $58 043 ), Robert Hariri (Sold 1 500 shares of value $20 400 ), Robert S. Stefanovich (Option Excercise at a value of $113 654), Robert S. Stefanovich (Sold 22 146 shares of value $482 568 ), Sawicki Mark (Sold 0 shares of value $-12 790 ), Sawicki Mark (Sold 2 838 shares of value $58 043 )
Thu, 13 Jul 2023 12:20 GMT Analysts Offer Insights on Healthcare Companies: CryoPort (CYRX) and Cara Therapeutics (CARA)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.